ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ゾピクロン

Zopiclone

HCID 5735
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
43200-80-2
標準SMILES
CN1CCN(C(=O)OC2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1
InChIKey
GBBSUAFBMRNDJC-UHFFFAOYSA-N
分子式
C17H17ClN6O3
平均分子量
388.8 g/mol
単同位体質量
388.10506608

概要

Zopiclone is a pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position. It has a role as a central nervous system depressant and a sedative. It is a monochloropyridine and a pyrrolopyrazine.

名称と識別子

優先名称
Zopiclone
IUPAC
[6-(5-chloro-2-pyridinyl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate
現地名
ゾピクロン
英語名
Zopiclone
分子式
C17H17ClN6O3
分子量
388.81

名称と別名

zopiclone43200-80-2ImovaneAmobanZimovane(+-)-ZopicloneZopiclonaZopiclonumXimovanRP-27267[6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylateRP 27267
名称をさらに表示
ゾピクール4-メチル-1-ピペラジンカルボン酸6-(5-クロロ-2-ピリジル)-6,7-ジヒドロ-7-オキソ-5H-ピロロ[3,4-b]ピラジン-5-イル4-メチルピペラジン-1-カルボン酸2-(5-クロロピリジン-2-イル)-3-オキソ-2,4,7-トリアザインダン-1-イルゾピバンアモバンアモバンテススローハイム4-メチル-1-ピペラジンカルボン酸6-(5-クロロ-2-ピリジニル)-6,7-ジヒドロ-7-オキソ-5H-ピロロ[3,4-b]ピラジン-5-イルドパリールメトロームゾピクロンゾピクロン (JAN)6-(5-クロロピリジン-2-イル)-7-オキソ-5H,6H,7H-ピロロ[3,4-b]ピラジン-5-イル 4-メチルピペラジン-1-カルボキシラート4-メチルピペラジン-1-カルボン酸(5-オキソ-6-(5-クロロ-2-ピリジル)-5,7-ジヒドロ-6H-ピロロ[3,4-b]ピラジン-7-イル)Zopiclone R-IsoMer CIV6-(5-Chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methyl-1-piperazinecarboxylateImobamLimovanAmovaneSopivanCS-1331
Zimovane LSNSC-75846303A5ORL08QZileze 7.5CHEBI:32315Zileze 3.751-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl esterDTXSID4041155

データベース識別子

CAS
43200-80-2
PubChem CID
5735
DTXSID
DTXSID4041155
ChEMBL
CHEMBL135400
ChEBI
CHEBI:32315
UNII
03A5ORL08Q
EC Number
256-138-9
Nikkaji
J16.885H

物性

構造計算による物性

XLogP
0.5
極性表面積
91.8 Ų
水素結合供与体数
0
水素結合受容体数
7
回転可能結合数
3
重原子数
27
形式電荷
0
複雑度
573

実験および物理化学的性質

Drugs · 5 件

DEA NFLIS-Drug Category -> Depressants and Tranquilizers

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals -> Hypnotic

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

Pharmaceuticals

LogP · 2 件

0.8

1.1

Solubility · 2 件

8.85e-01 g/L

>58.3 [ug/mL] (The mean of the results at pH 7.4)

Human DrugsPharmaceuticals
Melting Point178 °C
Physical DescriptionSolid
Collision Cross Section · 3 件

188.5 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

186.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

176.57 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
1780 C · 1780C
沸点
580.7 · 580.7±50.0 °C(Predicted)
比重(密度)
1.1105 · 1.1105 (estimate)
闪点
2 ℃ · 2℃
貯蔵温度
Store at RT
溶解性
2 mg/mL · DMSO: 2 mg/mL
酸解離定数(Pka)
1.5 · pKa ﹣1.5±0.1(10% ACN in aq. H2SO4 t = 25.0) (Uncertain)
外見
Solid
色
White to Off-White
安定性
Hygroscopic
主な用途
臨床検査
InChI
1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/p+1
InChIKey
GBBSUAFBMRNDJC-UHFFFAOYSA-N
SMILES
C[NH+]1CCN(CC1)C(=O)OC2N(C(=O)c3nccnc23)c4ccc(Cl)cn4
CAS データベース
43200 · 43200-80-2(CAS DataBase Reference)
NISTの化学物質情報
Zopiclone(43200-80-2)

化学的性質

化学的特性Crystalline Solid

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302+H312+H332 (20.1%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]

P203, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 139 reports by companies from 19 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 2 件

DEA schedule IV controlled substance

Zopiclone: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Hazard Classes and CategoriesAcute Tox. 4 (100%)

毒性情報

Health EffectsThey cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive.
Exposure RoutesRapidly absorbed following oral administration.
Toxicity Summary · 1 件

Zopiclone exerts its action by binding on the benzodiazepine receptor complex and modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex. Both zopiclone and benzodiazepines act indiscriminately at the benzodiazepine binding site on alpha1, alpha2, alpha3 and alpha5 GABAA containing receptors as full agonists causing an enhancement of the inhibitory actions of GABA to produce the therapeutic (hypnotic and anxiolytic) and adverse effects of zopiclone.

Signs and Symptoms · 1 件

Rare individual instances of fatal outcomes following overdose with racemic zopiclone have been reported in European postmarketing reports, most often associated with overdose with other CNS-depressant agent. Signs and symptoms of overdose effects of CNS depressants can be expected to present as exaggerations of the pharmacological effects noted in preclinical testing.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 4 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Zopiclone

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

安全データ

wgk
3
rtecs
TL1425000
ridadr
UN 1648 3 / PGII
毒性
mouse,LD50,intramuscular,541mg/kg (541mg/kg),LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSIONBEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY),Oyo Yakuri. Pharmacometrics. Vol. 26, Pg. 935, 1983.
hs_code
2933990099
risk_code
20/21/22-36/37/38-62-36-11
hazard_code
Xn,Xi,F
safety_code
26-36-36/37-16
Hazard Classifications
Acute Tox. 4 DermalAcute Tox. 4 InhalationAcute Tox. 4 OralEye Irrit. 2Flam. Liq. 2
ストレージクラス
3 - Flammable liquids

化学と産業

薬理情報

ATC Code · 3 件

N05CF01

N - Nervous system

QN - Nervous system

Protein BindingApproximately 45%
Pharmacodynamics · 1 件

Zopiclone is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABA<sub>B</sub>Z) receptor complex. Subunit modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zopiclone binds selectively to the brain alpha subunit of the GABA A omega-1 receptor.

Mechanism of Action · 1 件

Zopiclone exerts its action by binding on the benzodiazepine receptor complex and modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex. Both zopiclone and benzodiazepines act indiscriminately at the benzodiazepine binding site on α1, α2, α3 and α5 GABAA containing receptors as full agonists causing an enhancement of the inhibitory actions of GABA to produce the therapeutic (hypnotic and anxiolytic) and adverse effects of zopiclone.

Biological Half-LifeElimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.
Metabolism/Metabolites · 2 件

Extensively metabolized in the liver via decarboxylation (major pathway), demethylation, and side chain oxidation. Metabolites include an N-oxide derivative (weakly active; approximately 12% of a dose) and an N-desmethyl metabolite (inactive; approximately 16%). Approximately 50% of a dose is converted to other inactive metabolites via decarboxylation. Hepatic microsomal enzymes are apparently not involved in zopiclone clearance.

Extensively metabolized in the liver via decarboxylation (major pathway), demethylation, and side chain oxidation. Metabolites include an N-oxide derivative (weakly active; approximately 12% of a dose) and an N-desmethyl metabolite (inactive; approximately 16%). Approximately 50% of a dose is converted to other inactive metabolites via decarboxylation. Hepatic microsomal enzymes are apparently not involved in zopiclone clearance. Half Life: Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.

MeSH Pharmacological ClassificationDrugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
Absorption, Distribution and ExcretionRapidly absorbed following oral administration.
Cellular LocationsCytoplasm

用途と製造

Uses · 2 件

Use (kg; approx.) in Germany (2009): >500

For the short-term treatment of insomnia.

Use ClassificationPharmaceuticals
応用分野 · 4 件

用途ゾピクロン(英語: Zopiclone)は、シクロピロロン系の睡眠障害改善剤であり、非ベンゾジアゼピン系の超短時間作用型睡眠薬として知られている。GABA受容体へ影響することでGABA系の抑制機構を増強する点ではベンゾジアゼピン系の薬物と似ている。睡眠への影響では改良されている。

用途非ベンゾジアゼピン系化合物 です。ベンゾジアゼピン結合部位のω1 受容 体に作用します。

説明Zopiclone is an effective hypnotic agent with a short duration of action. Although it interacts with the benzodiazepine receptor complex, it is reported to have minimal effects on memory, little synergy with alcohol, and low abuse potential.

使用Cyclopyrrolone member of a family of non-benzodiazepine GABAA receptor agonists. This is a controlled substance (depressant) in the US but not in Canada. Sedative, hypnotic

上流・下流製品情報

上流原料

2-アミノ-5-クロロピリジンエリスロマイシンエストレートピラジンN,N-ジメチルホルムアミドピロール1-メチルピペラジンクロロホルムピペラジン1,4-ジオキサン水素化ほう素カリウム酢酸Anhydrous pyridineイソプロピルエーテル水酸化ナトリウム水素化ナトリウム(R)-Zopiclone6-(5-Chloro-pyridin-2-yl)-7-phenoxycarbonyloxy-6,7-dihydro-pyrrolo3,4-bpyrazin-5-oneエスゾピクロン

補足説明

定義ChEBI: A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.

関連反応

16 件
反応記録を作成
HRID 44214 の反応式
HRID 44214反応物として
HRID 113635 の反応式
HRID 113635反応物として
HRID 217643 の反応式
HRID 217643反応物として
HRID 217645 の反応式
HRID 217645反応物として
HRID 336391 の反応式
HRID 336391反応物として
HRID 454829 の反応式
HRID 454829反応物として
HRID 507798 の反応式
HRID 507798反応物として
HRID 507800 の反応式
HRID 507800生成物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート